CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy Expanded indication for this one-time infusion may provide pati.
Janssen-Cilag International NV, a Johnson & Johnson company, announced today that the European Commission has approved a type II variant for Carvykti . This latest approval is for the treatment of.
DelveInsight Business Research, LLP: Dry Age-related Macular Degeneration Seven Major Market to Exhibit Growth at a CAGR of 19.8% by 2034 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.